低剂量氟胞嘧啶治疗隐球菌脑膜炎的临床试验评估
FLOOR试验为2期单臂开放标签研究,纳入乌干达48例HIV合并隐球菌脑膜炎成人,评估氟胞嘧啶60 mg/kg/日联合脂质体两性霉素B和氟康唑的疗效。
要点
- 氟胞嘧啶60 mg/kg/日×10天的早期杀菌活性低于100 mg/kg/日历史对照。
- 18周生存概率77%,再住院率25%、培养阳性复发率6.3%均高于预期。
- 3-4级血液学毒性(白细胞减少10%、贫血21%)与历史发生率相似。
核心结论
- 氟胞嘧啶60 mg/kg/日×10天在脑脊液真菌清除方面疗效劣于100 mg/kg/日历史对照。
研究设计与样本
- 2期单臂开放标签试验,在乌干达2家医院纳入48例HIV合并隐球菌脑膜炎成人。
- 干预为氟胞嘧啶60 mg/kg/日分3次×10天,联合脂质体两性霉素B 10 mg/kg单次和氟康唑1200 mg/日×14天,后续标准巩固治疗。
- 主要终点为14天内脑脊液隐球菌清除率(早期杀菌活性),次要终点包括2周脑脊液无菌、18周生存和不良事件。
主要发现
- 18周估计生存概率77%(95%CI 66%-90%)。
- 再住院率25%,培养阳性复发率6.3%,均高于预期。
- 3-4级血液学毒性:白细胞减少10%,贫血21%,与历史发生率相似。
关键数值与推荐
- 氟胞嘧啶剂量60 mg/kg/日分3次,疗程10天。
- 脂质体两性霉素B 10 mg/kg单次给药。
- 氟康唑1200 mg/日,疗程14天。
临床怎么用
- 低剂量氟胞嘧啶(60 mg/kg/日)不推荐替代标准剂量100 mg/kg/日用于隐球菌脑膜炎诱导治疗。
- 需进一步研究剂量优化策略以平衡疗效与毒性。
局限性
- 单臂设计,无同期对照组,依赖历史对照比较。
- 样本量小(48例),来自乌干达2家医院,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cryptococcosis is a leading cause of death among people with human immunodeficeincy virus (HIV). Guidelines recommend combination therapy with amphotericin B and flucytosine, but standard flucytosine dosing of 100 mg/kg/day is associated with hematologic toxicity. The FLOOR trial investigated whether lower flucytosine dosing maintained therapeutic efficacy and reduced toxicity. METHODS: This phase 2, single-arm, open-label trial enrolled 48 adults with HIV and confirmed cryptococcal meningitis at 2 hospitals in Uganda. Participants received 10 days of flucytosine at 60 mg/kg/day in 3 divided doses, combined with liposomal amphotericin B (10 mg/kg, single dose) and fluconazole 1200 mg/day for 14 days, followed by standard consolidation therapy. The primary endpoint was the early fungicidal activity (EFA), which measures the rate of Cryptococcus clearance in the cerebrospinal fluid (CSF) in the first 14 days of therapy. Secondary endpoints included CSF sterility at 2 weeks, 18-week survival, and adverse events. RESULTS: The EFA of reduced dose flucytosine was 0.28 log10 colony forming units (CFU)/mL/day (95% CI, .20 to .35), which was lower than historical controls in Uganda receiving flucytosine at 100 mg/kg/day of 0.41 log10 CFU/mL/day (P = .019). At 18 weeks, the estimated survival probability was 77% (95% CI, 66% to 90%). The incidence of rehospitalization (25%) and culture-positive relapse (6.3%) were higher than expected. Grades 3 and 4 hematologic toxicity was similar (10% leukopenia; 21% anemia) to historical incidence. CONCLUSIONS: Reduced flucytosine dose of 60 mg/kg/day for 10 days demonstrated inferior efficacy in CSF fungal clearance. These findings support further investigation of dose optimization strategies. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06414512.
引用
- Rutakingirwa MK, Skipper CP, Dai B, et al. Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial. Clin Infect Dis. 2026. PMID: 40795226. doi:10.1093/cid/ciaf432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。